The sophisticated platform distinguishes individual patient profiles and issues and is used in a variety of ways “ by adults to simplify their own efforts to maintain healthy blood glucose levels; by concerned parents who receive automated notifications of their child ™s blood sugar levels while they are away at a school; and by pregnant mothers with a temporary form of the disease who depend on their doctors and nurses to guide them through a sharp learning curve. When prudent, GlucoMON-ADMS automatically connects the patient to family members, Diabetech's diabetes educators or any number of the world ™s finest outpatient diabetes programs including Driscoll Children ™s Hospital, Texas Children ™s Hospital, Baylor Health Care System, Kaiser Permanente Center for Health Research / Southeast and others.
In the past eight years working on more than a dozen clinical trials and many system refinements, we ™ve created an intuitive health platform that simplifies patient tasks, creates more efficiencies for providers, significantly improves blood sugar control and decreases costs to the health care system at large, said Kevin McMahon, Diabetech ™s CEO. We selected Cinterion for their market leading expertise and high quality M2M products that allowed us to quickly and easily migrate away from previous networks and scale the platform with confidence. With Cinterion ™s superior engineering and technology, GlucoMON is now relevant to people worldwide as a catalyst for changing behaviors and improving overall well-being for those struggling with silent killers like diabetes.
Telehealth M2M solutions such as GlucoMON-ADMS are a quickly growing market segment for their ability to cut medical costs and help manage chronic disease. A study released this summer by ABI Research projects that there will be approximately 15 million wireless telehealth sensors and devices in use by 2012, or more than double the number of wireless telehealth systems in use today. In addition to its expanding availability in the U.S., Diabetech is underway with trial design for type 1 and type 2 diabetes in pregnancy in addition to hospital-based use in the UK with its first UK patient expected in early 2010.
cinterion/